| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ticlatone targets microbial proteins through mercury-mediated interactions. It disrupts protein function in fungi and bacteria, leading to microbial cell death.
|
|---|---|
| ln Vitro |
In vitro, Ticlatone exhibits antifungal and antibacterial activity. It is used in microbiological research for the investigation and treatment of various pathogenic mycoses and fungal infections. The compound acts by disrupting microbial proteins through mercury-mediated interactions.
|
| ln Vivo |
In vivo, Ticlatone was used topically to treat skin and mucosal infections. Its clinical use declined due to risks of local irritation and systemic mercury toxicity. The compound is now considered obsolete and is used primarily for research in microbiology and chemical biology.
|
| Enzyme Assay |
Non-cell assays for Ticlatone are not typical as the compound acts through direct protein interactions rather than receptor binding. Mechanism of action studies focus on mercury-mediated protein disruption. Protein binding and thiol reactivity assays are performed using model proteins (e.g., bovine serum albumin) incubated with Ticlatone at concentrations of 0.1-100 μg/mL. Protein modification is assessed by SDS-PAGE, mass spectrometry, or thiol quantification using Ellman's reagent. Antimicrobial activity is assessed by standard broth microdilution methods.
|
| Cell Assay |
Cellular assays for Ticlatone are performed using standard broth microdilution methods according to CLSI guidelines. Fungal and bacterial cultures are grown to mid-log phase and diluted to ~5×10⁵ CFU/mL. Two-fold serial dilutions of Ticlatone are prepared in 96-well plates. Microorganisms are added and incubated at 37°C (bacteria) or 30°C (fungi) for 18-24 hours. The MIC is determined as the lowest concentration with no visible growth. MBC/MFC is determined by subculturing onto agar plates. Cytotoxicity is evaluated using mammalian cell lines with MTT assays.
|
| Animal Protocol |
In vivo animal studies for Ticlatone were historically conducted in models of topical fungal or bacterial infections. Ticlatone was administered topically as an ointment or cream. Efficacy endpoints included reduction in lesion size, microbial load, and clinical cure rates. These studies are now largely obsolete due to the compound's toxicity profile.
|
| ADME/Pharmacokinetics |
Ticlatone has a molecular weight of 185.63 and a molecular formula of C7H4ClNOS. It is also known as Landromil or FER-1443. Ticlatone is a yellow to off-white crystalline solid. The compound is typically stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
Ticlatone belongs to the organic-mercury class and carries risks of local irritation and systemic mercury toxicity. Clinical use declined due to these safety concerns. No significant toxicology data are available for research use. The compound is considered obsolete for therapeutic use.
|
| Additional Infomation |
Ticladone belongs to the benzothiazole class of compounds.
Ticlatone (Landromil) is a synthetic antifungal and antibacterial compound belonging to the organic-mercury class. It was once used topically to treat skin and mucosal infections but its clinical use declined due to mercury toxicity. Ticlatone is now considered obsolete and is used primarily for research in microbiology. |
| Molecular Formula |
C7H4CLNOS
|
|---|---|
| Molecular Weight |
185.625
|
| Exact Mass |
184.97
|
| CAS # |
70-10-0
|
| PubChem CID |
6258
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.515 g/cm3
|
| Melting Point |
270-272ºC
|
| Index of Refraction |
1.669
|
| LogP |
2.243
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
187
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC2=C(C=C1Cl)SN=C2O
|
| InChi Key |
POPOYOKQQAEISW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H4ClNOS/c8-4-1-2-5-6(3-4)11-9-7(5)10/h1-3H,(H,9,10)
|
| Chemical Name |
6-chloro-1,2-benzothiazol-3-one
|
| Synonyms |
FER-1443; Landromil; Ticlatone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~673.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3871 mL | 26.9353 mL | 53.8706 mL | |
| 5 mM | 1.0774 mL | 5.3871 mL | 10.7741 mL | |
| 10 mM | 0.5387 mL | 2.6935 mL | 5.3871 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
